Strata Critical Medical

SRTA on Nasdaq. Strata sells organ transport and surgical services to transplant hospitals and organ procurement groups. Market value $492m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Industrials stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
0.2%low

For every $100 of what the whole company costs, it produced $0.20 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 40 of 100. Price score: 1 of 100. Our list needs 70 on quality and 60 on price.

$4.56 a share, 15% above its 1-year low

Over the past year the price has ranged from $3.95 to $6.50.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.0
-0.0
-0.0
-0.0
-0.1
0.0
2021202220232024202512 monthsto Sep '26

Spare cash swings from quarter to quarter here: $806,000 in the past 12 months, a shortfall of $59 million in the year to December 2025.

Revenue
$51m$146m$225m$147m$197m
Operating margin
-47.7%-36.6%-30.3%-15.3%-11.3%
Debt to equity
n/a0.00n/an/an/a
Shares outstanding
0.07bn0.07bn0.08bn0.09bn0.09bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)4 of 7 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsStrong, 37.7% a year
  • Buying back its own sharesNo, 25% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $74 million last quarter, up 50% on a year ago.
  • A loss of $8 million, after a profit of $57 million a year ago.
  • It loses 7 cents on each $1 of sales, compared with 13 cents a year earlier.
  • Spare cash over the past 12 months: $806,000. A year earlier it spent $55 million more than it brought in.
  • 7% more shares than a year ago. Each share owns a bit less of the company.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$36m
March 2025$36m
June 2025$45m
September 2025$49m
December 2025Not reported
March 2026$67m
June 2026$73m
September 2026$74m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$10m
March 2025-$3m
June 2025-$4m
September 2025$57m
December 2025-$9m
March 2026$2m
June 2026-$11m
September 2026-$8m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
3 March 2026
Next quarterly (estimated, 10-Q)
2 February 2027

Who owns it

4 long-term investors we follow own it, unchanged from 4 last quarter. 139 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%; 1 of them is pushing for change.

  • Steele ExpCo Holdings, LLC
    Passive investor
    at least 9.0%
    (filed with 2 related holders)
    Since 30 June 2026
  • Third Point
    Activist
    at least 5.8%0.0 pts
    (filed with 1 related holder)
    Since 13 October 2026
    What they said

    The Reporting Persons acquired the securities reported herein for investment purposes and believe that the Common Stock is undervalued. The Reporting Persons believe that the underlying business of the Issuer is strong, but not of a scale to support its current overhead and that…

    Read the filing
  • Daniel S. Loeb
    Passive investor
    5.8%−0.3 pts
    Since 30 September 2025
  • at least 5.1%
    (filed with 5 related holders)
    Since 11 June 2026
  • BlackRock, Inc.
    Passive investor
    5.1%+0.1 pts
    Since 31 December 2025
  • at least 3.2%−5.4 pts
    (filed with 1 related holder)
    Since 30 June 2026
  • Krstic Velibor
    Activist
    Sold down below 5%
    Since 7 May 2026
    What they said

    This Amendment No. 3 is being filed to report that the 1,577,500 Warrants previously held by the Reporting Person (SRTAW) expired worthless on May 7, 2026, in accordance with the terms of the Warrant Agreement dated September 12, 2019. As a result of this expiration, the…

    Read the filing

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 2 insiders bought $107,838 of shares on the open market. 2 sold $411,540, $382,267 of it under preset trading plans.

  • LAUCK ANDREW
    Director
    Bought
    Date
    5 November 2026
    Shares
    2,000
    Price
    $5.00
    Value
    $9,998
  • Love Reginald
    Director
    Sold
    Date
    10 August 2026
    Shares
    5,091
    Price
    $5.75
    Value
    $29,273
  • Cohen Amir
    Chief Accounting Officer
    Sold
    under a preset trading plan
    Date
    22 May 2026
    Shares
    40,575
    Price
    $5.91
    Value
    $239,798
  • Cohen Amir
    Chief Accounting Officer
    Sold
    under a preset trading plan
    Date
    21 May 2026
    Shares
    10,300
    Price
    $5.79
    Value
    $59,637
  • Cohen Amir
    Chief Accounting Officer
    Sold
    under a preset trading plan
    Date
    11 May 2026
    Shares
    14,306
    Price
    $5.79
    Value
    $82,832
  • Heyburn William A.
    Co-CEO and CFO, Director
    Bought
    Date
    9 December 2025
    Shares
    17,000
    Price
    $4.47
    Value
    $75,990
  • LAUCK ANDREW
    Director
    Bought
    Date
    5 December 2025
    Shares
    5,000
    Price
    $4.37
    Value
    $21,850

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 3 Mar 2026, plus the 10-Q filed 3 Nov 2026 and 4 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • Profits run ahead of cash.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.